Cardiomyopathy and kidney function in agalsidase beta‐treated female Fabry patients: a pre‐treatment vs. post‐treatment analysis

Abstract Aims Long‐term treatment effect studies in large female Fabry patient groups are challenging to design because of phenotype heterogeneity and lack of appropriate comparison groups, and have not been reported. We compared long‐term cardiomyopathy and kidney function outcomes after agalsidase...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Christoph Wanner, Ulla Feldt‐Rasmussen, Ana Jovanovic, Aleš Linhart, Meng Yang, Elvira Ponce, Eva Brand, Dominique P. Germain, Derralynn A. Hughes, John L. Jefferies, Ana Maria Martins, Albina Nowak, Bojan Vujkovac, Frank Weidemann, Michael L. West, Alberto Ortiz
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Oxford University Press 2020-06-01
Serie:	ESC Heart Failure
Soggetti:	Agalsidase beta Enzyme replacement therapy Fabry disease Cardiomyopathy Kidney function Female patients
Accesso online:	https://doi.org/10.1002/ehf2.12647
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!